[DOI] [PubMed] [Google Scholar] 25.Kosiborod M.N., Abildstrom S.Z., Borlaug B.A., Butler J., Rasmussen S., Davies M., Hovingh G.K., Kitzman D.W., Lindegaard M.L., Moller D.V., et al
however, the rarity of SIS events and the wide uncertainty of effect size (although null, effect may be compatible with a risk as high as threefold) calls for a cautious interpretation of our results
Patients who stop treatment often regain weight, especially if lifestyle changes havent been fully integrated
The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials
The problem is that the market has commoditized nearly as rapidly as it has grown
But it's so worth it